Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1999 May;66(5):575–580. doi: 10.1136/jnnp.66.5.575

Successful treatment of IgM paraproteinaemic neuropathy with fludarabine

H Wilson 1, M Lunn 1, S Schey 1, R Hughes 1
PMCID: PMC1736362  PMID: 10209166

Abstract

OBJECTIVES—To evaluate the response of four patients with IgM paraproteinaemic neuropathy to a novel therapy—pulsed intravenous fludarabine.
BACKGROUND—The peripheral neuropathy associated with IgM paraproteinaemia usually runs a chronic, slowly progressive course which may eventually cause severe disability. Treatment with conventional immunosuppressive regimens has been unsatisfactory. Fludarabine is a novel purine analogue which has recently been shown to be effective in low grade lymphoid malignancies.
METHODS—Four patients were treated with IgM paraproteinaemic neuropathy with intravenous pulses of fludarabine. Two of the four patients had antibodies to MAG and characteristic widely spaced myelin on nerve biopsy and a third had characteristic widely spaced myelin only. The fourth had an endoneurial lymphocytic infiltrate on nerve biopsy and a diagnosis of Waldenström's macroglobulinaemia.
RESULTS—In all cases subjective and objective clinical improvement occurred associated with a significant fall in the IgM paraprotein concentration in three cases. Neurophysiological parameters improved in the three patients examined. The treatment was well tolerated. All patients developed mild, reversible lymphopenia and 50% mild generalised myelosuppression, but there were no febrile episodes.
CONCLUSION—Fludarabine should be considered as a possible treatment for patients with IgM MGUS paraproteinaemic neuropathy.



Full Text

The Full Text of this article is available as a PDF (119.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adkins J. C., Peters D. H., Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs. 1997 Jun;53(6):1005–1037. doi: 10.2165/00003495-199753060-00007. [DOI] [PubMed] [Google Scholar]
  2. Blume G., Pestronk A., Goodnough L. T. Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Neurology. 1995 Aug;45(8):1577–1580. doi: 10.1212/wnl.45.8.1577. [DOI] [PubMed] [Google Scholar]
  3. Cook D., Dalakas M., Galdi A., Biondi D., Porter H. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology. 1990 Feb;40(2):212–214. doi: 10.1212/wnl.40.2.212. [DOI] [PubMed] [Google Scholar]
  4. Dalakas M. C., Engel W. K. Polyneuropathy with monoclonal gammopathy: studies of 11 patients. Ann Neurol. 1981 Jul;10(1):45–52. doi: 10.1002/ana.410100109. [DOI] [PubMed] [Google Scholar]
  5. Dalakas M. C., Quarles R. H., Farrer R. G., Dambrosia J., Soueidan S., Stein D. P., Cupler E., Sekul E. A., Otero C. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol. 1996 Nov;40(5):792–795. doi: 10.1002/ana.410400516. [DOI] [PubMed] [Google Scholar]
  6. Donofrio P. D., Kelly J. J., Jr AAEE case report #17: Peripheral neuropathy in monoclonal gammopathy of undetermined significance. Muscle Nerve. 1989 Jan;12(1):1–8. doi: 10.1002/mus.880120102. [DOI] [PubMed] [Google Scholar]
  7. Dyck P. J., Low P. A., Windebank A. J., Jaradeh S. S., Gosselin S., Bourque P., Smith B. E., Kratz K. M., Karnes J. L., Evans B. A. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med. 1991 Nov 21;325(21):1482–1486. doi: 10.1056/NEJM199111213252105. [DOI] [PubMed] [Google Scholar]
  8. Ernerudh J. H., Vrethem M., Andersen O., Lindberg C., Berlin G. Immunochemical and clinical effects of immunosuppressive treatment in monoclonal IgM neuropathy. J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):930–934. doi: 10.1136/jnnp.55.10.930. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ernerudh J., Brodtkorb E., Olsson T., Vedeler C. A., Nyland H., Berlin G. Peripheral neuropathy and monoclonal IgM with antibody activity against peripheral nerve myelin; effect of plasma exchange. J Neuroimmunol. 1986 May;11(3):171–178. doi: 10.1016/0165-5728(86)90001-9. [DOI] [PubMed] [Google Scholar]
  10. Gorson K. C., Allam G., Ropper A. H. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology. 1997 Feb;48(2):321–328. doi: 10.1212/wnl.48.2.321. [DOI] [PubMed] [Google Scholar]
  11. Haas D. C., Tatum A. H. Plasmapheresis alleviates neuropathy accompanying IgM anti-myelin-associated glycoprotein paraproteinemia. Ann Neurol. 1988 Apr;23(4):394–396. doi: 10.1002/ana.410230415. [DOI] [PubMed] [Google Scholar]
  12. Hughes R. A., Stedronska J. The susceptibility of rat strains to experimental allergic encephalomyelitis. Immunology. 1973 May;24(5):879–884. [PMC free article] [PubMed] [Google Scholar]
  13. Keating M. J., O'Brien S., Plunkett W., Robertson L. E., Gandhi V., Estey E., Dimopoulos M., Cabanillas F., Kemena A., Kantarjian H. Fludarabine phosphate: a new active agent in hematologic malignancies. Semin Hematol. 1994 Jan;31(1):28–39. [PubMed] [Google Scholar]
  14. Kelly J. J., Adelman L. S., Berkman E., Bhan I. Polyneuropathies associated with IgM monoclonal gammopathies. Arch Neurol. 1988 Dec;45(12):1355–1359. doi: 10.1001/archneur.1988.00520360073015. [DOI] [PubMed] [Google Scholar]
  15. Kelly J. J., Jr, Kyle R. A., O'Brien P. C., Dyck P. J. Prevalence of monoclonal protein in peripheral neuropathy. Neurology. 1981 Nov;31(11):1480–1483. doi: 10.1212/wnl.31.11.1480. [DOI] [PubMed] [Google Scholar]
  16. Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol. 1995 May;37 (Suppl 1):S32–S42. doi: 10.1002/ana.410370705. [DOI] [PubMed] [Google Scholar]
  17. Leger J. M., Younes-Chennoufi A. B., Chassande B., Davila G., Bouche P., Baumann N., Brunet P. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry. 1994 Nov;57 (Suppl):46–49. doi: 10.1136/jnnp.57.suppl.46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Mariette X., Chastang C., Clavelou P., Louboutin J. P., Leger J. M., Brouet J. C. A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry. 1997 Jul;63(1):28–34. doi: 10.1136/jnnp.63.1.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Melmed C., Frail D., Duncan I., Braun P., Danoff D., Finlayson M., Stewart J. Peripheral neuropathy with IgM kappa monoclonal immunoglobulin directed against myelin-associated glycoprotein. Neurology. 1983 Nov;33(11):1397–1405. doi: 10.1212/wnl.33.11.1397. [DOI] [PubMed] [Google Scholar]
  20. Montillo M., Mirto S., Petti M. C., Latagliata R., Magrin S., Pinto A., Zagonel V., Mele G., Tedeschi A., Ferrara F. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol. 1998 Jun;58(2):105–109. doi: 10.1002/(sici)1096-8652(199806)58:2<105::aid-ajh3>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  21. Nobile-Orazio E., Baldini L., Barbieri S., Marmiroli P., Spagnol G., Francomano E., Scarlato G. Treatment of patients with neuropathy and anti-MAG IgM M-proteins. Ann Neurol. 1988 Jul;24(1):93–97. doi: 10.1002/ana.410240118. [DOI] [PubMed] [Google Scholar]
  22. Nokes T. J., Johnson S., Harvey D., Goldstone A. H. FLAG is a useful regimen for poor prognosis adult myeloid leukaemias and myelodysplastic syndromes. Leuk Lymphoma. 1997 Sep;27(1-2):93–101. doi: 10.3109/10428199709068275. [DOI] [PubMed] [Google Scholar]
  23. Notermans N. C., Lokhorst H. M., Franssen H., Van der Graaf Y., Teunissen L. L., Jennekens F. G., Van den Berg L. H., Wokke J. H. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology. 1996 Nov;47(5):1227–1233. doi: 10.1212/wnl.47.5.1227. [DOI] [PubMed] [Google Scholar]
  24. Notermans N. C., Vermeulen M., Lokhorst H. M., Van Doorn P. A., Van den Berg L. H., Teunissen L. L., Wokke J. H. Pulsed high-dose dexamethasone treatment of polyneuropathy associated with monoclonal gammopathy. J Neurol. 1997 Jul;244(7):462–463. doi: 10.1007/s004150050124. [DOI] [PubMed] [Google Scholar]
  25. O'Brien M. E., Matutes E., Cunningham D., Hill M., Emmett E., Ellis P. A., Milan S., Hickish T., Mercieca J., Catovsky D. Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience. Leuk Lymphoma. 1994;14 (Suppl 2):17–23. doi: 10.3109/10428199409052691. [DOI] [PubMed] [Google Scholar]
  26. O'Brien S., Kantarjian H., Keating M. J. Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia. Ann Oncol. 1996;7 (Suppl 6):S27–S33. doi: 10.1093/annonc/7.suppl_6.s27. [DOI] [PubMed] [Google Scholar]
  27. Oksenhendler E., Chevret S., Léger J. M., Louboutin J. P., Bussel A., Brouet J. C. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry. 1995 Sep;59(3):243–247. doi: 10.1136/jnnp.59.3.243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sherman W. H., Olarte M. R., McKiernan G., Sweeney K., Latov N., Hays A. P. Plasma exchange treatment of peripheral neuropathy associated with plasma cell dyscrasia. J Neurol Neurosurg Psychiatry. 1984 Aug;47(8):813–819. doi: 10.1136/jnnp.47.8.813. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Siciliano G., Moriconi L., Gianni G., Richieri E., Vignocchi M. G., Rossi B. Selective techniques of apheresis in polyneuropathy associated with monoclonal gammopathy of undetermined significance. Acta Neurol Scand. 1994 Feb;89(2):117–122. doi: 10.1111/j.1600-0404.1994.tb01646.x. [DOI] [PubMed] [Google Scholar]
  30. Smith T., Sherman W., Olarte M. R., Lovelace R. E. Peripheral neuropathy associated with plasma cell dyscrasia: a clinical and electrophysiological follow-up study. Acta Neurol Scand. 1987 Apr;75(4):244–248. doi: 10.1111/j.1600-0404.1987.tb07927.x. [DOI] [PubMed] [Google Scholar]
  31. Tatum A. H. Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelin-associated glycoprotein. Ann Neurol. 1993 May;33(5):502–506. doi: 10.1002/ana.410330514. [DOI] [PubMed] [Google Scholar]
  32. Yeung K. B., Thomas P. K., King R. H., Waddy H., Will R. G., Hughes R. A., Gregson N. A., Leibowitz S. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings. J Neurol. 1991 Oct;238(7):383–391. doi: 10.1007/BF00319857. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES